-
On April 16, 2025, the U.S. FDA released the latest Drug Master File (DMF) list. Xiushi Biopharma's Semaglutide product, produced with a breakthrough bioprocess, successfully made the list (DMF number: 041460). This milestone achievement not only demonstrates Xiushi Biopharma's innovative strength b
-
Xiushi Biopharma and Lechun Biotech have reached a strategic cooperation to jointly build an intelligent production line for synthetic biology peptide projectsWang Feng, CEO of LePure Biotech"In recent years,LePure Biotech has been continuously optimizing its core competitiveness and actively seekin
-
Deepening our presence in the GLP-1 field, BoYun Biotech and Xiu Shi Biopharma have reached a strategic cooperation agreement.On August 30th, Tianjin Boyun Purification Equipment Materials Technology Co., Ltd. ("Boyun Biotech") and Xiu Shi Biopharma (Nantong) Co., Ltd. ("Xiu Shi Biopharma") held a s
-
Xiushi Biopharma and Lechun Biotech have reached a strategic cooperation to jointly build an intelligent production line for synthetic biology peptide projectsWang Feng, CEO of LePure Biotech"In recent years,LePure Biotech has been continuously optimizing its core competitiveness and actively seekin
-
Recently, Xiu Shi Biopharma ceutical (Nantong) Co., Ltd. (hereinafter referred to as "Xiu Shi Biopharma ceutical") announced that it has completed a multi-million yuan angel round financing, with exclusive investment from Shicui Capital. The funds from this round of financing will be mainly used to
